SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cogent Biosciences, Inc. – ‘424B3’ on 12/1/20

On:  Tuesday, 12/1/20, at 8:45pm ET   ·   As of:  12/2/20   ·   Accession #:  1193125-20-307560   ·   File #:  333-230678

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/02/20  Cogent Biosciences, Inc.          424B3                  1:49K                                    Donnelley … Solutions/FA

Prospectus – New Facts or Events   —   Rule 424(b)(3)
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 424B3       Prospectus - New Facts or Events                    HTML      5K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  424B3  

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-230678

 

LOGO

PROSPECTUS SUPPLEMENT NO. 1

TO PROSPECTUS DATED MAY 1, 2019

This Prospectus Supplement No. 1 supplements and amends the prospectus dated May 1, 2019 (the “Prospectus”), covering the offering, issuance and sale of up to a maximum aggregate offering price of $50,000,000 (the “Maximum Offering Price”) of our common stock that may be issued and sold under a sales agreement with Cowen and Company, LLC (the “ATM Facility”).

Effective as of December 1, 2020, we have reduced the Maximum Offering Price to $9,500,000. As of the date of this prospectus supplement, no shares have been sold under the ATM Facility.

You should read this prospectus supplement, together with additional information described under the headings “Incorporation by Reference” and “Where You Can Find More Information” in the Prospectus carefully before you invest in our securities.

Investing in our securities involves a high degree of risk. Before making any investment in these securities, you should consider carefully the risks and uncertainties described in the section entitled “Risk Factors” beginning on page S-2 of the Prospectus.

The date of this prospectus supplement is December 1, 2020.


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘424B3’ Filing    Date    Other Filings
Filed as of:12/2/20424B5,  8-K
Filed on:12/1/204,  8-K
5/1/19EFFECT
 List all Filings 
Top
Filing Submission 0001193125-20-307560   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 3:25:01.1am ET